Bausch & Lomb Corp
Company Profile
Business description
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Contact
520 Applewood Crescent
VaughanONL4K 4B4
CANT: +1 905 695-7700
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
13,500
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,157.90 | 0.80 | -0.01% |
CAC 40 | 8,042.95 | 51.25 | -0.63% |
DAX 40 | 22,891.68 | 107.47 | -0.47% |
Dow JONES (US) | 41,985.35 | 32.03 | 0.08% |
FTSE 100 | 8,646.79 | 55.20 | -0.63% |
HKSE | 23,652.96 | 36.76 | -0.16% |
NASDAQ | 17,784.05 | 92.42 | 0.52% |
Nikkei 225 | 37,659.63 | 17.43 | -0.05% |
NZX 50 Index | 12,128.21 | 14.67 | 0.12% |
S&P 500 | 5,667.56 | 4.67 | 0.08% |
S&P/ASX 200 | 7,936.90 | 5.70 | 0.07% |
SSE Composite Index | 3,348.79 | 16.04 | -0.48% |